Proteome Sciences PLC (PRM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Proteome Sciences PLC (PRM) has a cash flow conversion efficiency ratio of -0.089x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX851.00K ≈ $103.54 USD) by net assets (GBX-9.53 Million ≈ $-1.16K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PRM defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Proteome Sciences PLC - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Proteome Sciences PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Proteome Sciences PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Proteome Sciences PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Verici Dx Plc
LSE:VRCI
|
-1.091x |
|
Sutton Harbour Holdings plc
LSE:SUH
|
-0.042x |
|
Walker Crips Group PLC
LSE:WCW
|
-0.456x |
|
TROUBADOUR RESOURCES INC.
F:2QD0
|
-0.017x |
|
Seed Innovations Ltd
LSE:SEED
|
-0.032x |
|
CPPGroup Plc
LSE:CPP
|
-7.401x |
|
Mothercare PLC
LSE:MTC
|
0.109x |
|
Vincerx Pharma, Inc. Common Stock
NASDAQ:VINC
|
-2.156x |
Annual Cash Flow Conversion Efficiency for Proteome Sciences PLC (1994–2025)
The table below shows the annual cash flow conversion efficiency of Proteome Sciences PLC from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see Proteome Sciences PLC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX-9.53 Million ≈ $-1.16K |
GBX-46.00K ≈ $-5.60 |
0.005x | -96.19% |
| 2024-12-31 | GBX-6.52 Million ≈ $-792.81 |
GBX-826.00K ≈ $-100.50 |
0.127x | -19.20% |
| 2023-12-31 | GBX-3.07 Million ≈ $-373.04 |
GBX-481.00K ≈ $-58.52 |
0.157x | +507640.31% |
| 2022-12-31 | GBX69.26 Billion ≈ $8.43 Million |
GBX2.14 Million ≈ $260.38 |
0.000x | +172.90% |
| 2021-12-31 | GBX70.04 Billion ≈ $8.52 Million |
GBX793.00K ≈ $96.49 |
0.000x | -52.16% |
| 2020-12-31 | GBX66.88 Billion ≈ $8.14 Million |
GBX1.58 Million ≈ $192.61 |
0.000x | +100.01% |
| 2019-12-31 | GBX65.66 Billion ≈ $7.99 Million |
GBX-21.45 Billion ≈ $-2.61 Million |
-0.327x | -40.98% |
| 2018-12-31 | GBX63.78 Billion ≈ $7.76 Million |
GBX-14.78 Billion ≈ $-1.80 Million |
-0.232x | -127.58% |
| 2017-12-31 | GBX66.02 Billion ≈ $8.03 Million |
GBX55.47 Billion ≈ $6.75 Million |
0.840x | +3000.54% |
| 2016-12-31 | GBX1.09 Trillion ≈ $133.11 Million |
GBX-31.70 Billion ≈ $-3.86 Million |
-0.029x | -104.09% |
| 2015-12-31 | GBX65.86 Billion ≈ $8.01 Million |
GBX46.63 Billion ≈ $5.67 Million |
0.708x | +845.17% |
| 2014-12-31 | GBX65.96 Billion ≈ $8.03 Million |
GBX-6.27 Billion ≈ $-762.51K |
-0.095x | +47.39% |
| 2013-12-31 | GBX63.95 Billion ≈ $7.78 Million |
GBX-11.55 Billion ≈ $-1.41 Million |
-0.181x | -104.13% |
| 2012-12-31 | GBX-766.53K ≈ $-93.26 |
GBX-3.35 Million ≈ $-408.01 |
4.375x | +379.37% |
| 2011-12-31 | GBX3.30 Million ≈ $401.39 |
GBX-5.17 Million ≈ $-628.55 |
-1.566x | -382.40% |
| 2010-12-31 | GBX7.22 Million ≈ $878.34 |
GBX4.00 Million ≈ $487.05 |
0.555x | +72.36% |
| 2009-12-31 | GBX-9.24 Million ≈ $-1.12K |
GBX-2.97 Million ≈ $-361.61 |
0.322x | -56.11% |
| 2008-12-31 | GBX-5.62 Million ≈ $-684.28 |
GBX-4.12 Million ≈ $-501.53 |
0.733x | -61.23% |
| 2007-12-31 | GBX-2.17 Million ≈ $-263.42 |
GBX-4.09 Million ≈ $-498.00 |
1.891x | +235.68% |
| 2006-12-31 | GBX2.59 Million ≈ $314.88 |
GBX-3.61 Million ≈ $-438.75 |
-1.393x | -129.38% |
| 2005-12-31 | GBX7.85 Million ≈ $955.24 |
GBX-4.77 Million ≈ $-580.25 |
-0.607x | -41.83% |
| 2004-12-31 | GBX8.80 Million ≈ $1.07K |
GBX-3.77 Million ≈ $-458.72 |
-0.428x | -4.05% |
| 2003-12-31 | GBX11.84 Million ≈ $1.44K |
GBX-4.88 Million ≈ $-593.15 |
-0.412x | -48.86% |
| 2002-12-31 | GBX11.84 Million ≈ $1.44K |
GBX-3.27 Million ≈ $-398.35 |
-0.276x | +55.36% |
| 2001-12-31 | GBX2.51 Million ≈ $305.27 |
GBX-1.55 Million ≈ $-189.08 |
-0.619x | -43.31% |
| 2000-12-31 | GBX2.64 Million ≈ $321.21 |
GBX-1.14 Million ≈ $-138.83 |
-0.432x | +96.38% |
| 1999-12-31 | GBX105.00K ≈ $12.78 |
GBX-1.25 Million ≈ $-152.58 |
-11.943x | -698.00% |
| 1998-12-31 | GBX1.03 Million ≈ $125.44 |
GBX-1.54 Million ≈ $-187.74 |
-1.497x | -233.77% |
| 1997-12-31 | GBX2.87 Million ≈ $348.95 |
GBX-1.29 Million ≈ $-156.47 |
-0.448x | +91.59% |
| 1996-12-31 | GBX321.00K ≈ $39.06 |
GBX-1.71 Million ≈ $-208.30 |
-5.333x | -278.00% |
| 1994-10-31 | GBX-270.00K ≈ $-32.85 |
GBX-809.00K ≈ $-98.43 |
2.996x | -- |
About Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more